More than 30 agents conducted a surprise raid of Sanofi’s headquarters in Paris on Tuesday morning as part of a tax fraud ...

AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the ...

Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...

Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add ...

A recent survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of ...

The U.K. drug marketing watchdog has ruled that a presentation calling the European Medicines Agency (EMA) “stupid” brought ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to ...

This fall, Fierce Pharma Marketing launched a running series of Q&A features celebrating up-and-comers in our corner of the ...

| Adopting an RTU vial setup for aseptic filling process can help optimize operational efficiency, reduce TCO, and comply ...

When the FDA reworked the prescribing information for Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy Elevidys earlier this month, the company touted a plan to study a regimen | ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...